{
    "ticker": "GOVXW",
    "name": "GeoVax Labs, Inc.",
    "description": "GeoVax Labs, Inc. is a biotechnology company focused on the development and commercialization of innovative vaccines and immunotherapies for infectious diseases and cancer. Founded in 2001 and headquartered in Atlanta, Georgia, GeoVax is committed to addressing global health challenges through cutting-edge technologies and research. The company\u2019s core platform utilizes a unique viral vector technology that has shown promise in preclinical and clinical trials for various diseases. Notably, GeoVax is advancing its development of vaccines for HIV, Zika virus, and COVID-19, aiming to provide effective solutions to significant public health threats. Their lead product candidates include GeoVax's DNA vaccine platform, which leverages a safe and efficient approach to stimulate immune responses. The company partners with academic institutions and research organizations to enhance its product pipeline and accelerate the development process. With a focus on innovation, GeoVax is positioned to make substantial contributions to the fields of infectious disease prevention and cancer treatment, working to improve patient outcomes globally.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Atlanta, Georgia, USA",
    "founded": "2001",
    "website": "https://www.geovax.com",
    "ceo": "David D. Brunner",
    "social_media": {
        "twitter": "https://twitter.com/geovax",
        "linkedin": "https://www.linkedin.com/company/geovax-labs-inc/"
    },
    "investor_relations": "https://www.geovax.com/investor-relations",
    "key_executives": [
        {
            "name": "David D. Brunner",
            "position": "CEO"
        },
        {
            "name": "Robert M. Karr",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Vaccines",
            "products": [
                "HIV Vaccine",
                "Zika Vaccine",
                "COVID-19 Vaccine"
            ]
        },
        {
            "category": "Immunotherapies",
            "products": [
                "Cancer Immunotherapy"
            ]
        }
    ],
    "seo": {
        "meta_title": "GeoVax Labs, Inc. | Innovative Vaccines and Immunotherapies",
        "meta_description": "GeoVax Labs, Inc. is dedicated to developing vaccines and immunotherapies for infectious diseases and cancer, focusing on innovative solutions to global health challenges.",
        "keywords": [
            "GeoVax",
            "Vaccines",
            "Immunotherapy",
            "HIV Vaccine",
            "Zika Virus",
            "COVID-19 Vaccine",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What does GeoVax specialize in?",
            "answer": "GeoVax specializes in developing vaccines and immunotherapies for infectious diseases and cancer."
        },
        {
            "question": "Where is GeoVax headquartered?",
            "answer": "GeoVax is headquartered in Atlanta, Georgia, USA."
        },
        {
            "question": "What are some of GeoVax's key products?",
            "answer": "Key products include vaccines for HIV, Zika virus, and COVID-19."
        },
        {
            "question": "When was GeoVax founded?",
            "answer": "GeoVax was founded in 2001."
        }
    ],
    "competitors": [
        "NVAX",
        "MRNA",
        "PFE",
        "BNTX"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}